Table 2 Comparison of basic information between this NMA and other 2 studies

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study | Database | Retrieval time | Disease | Intervention VS control | Outcome | GRADE evaluation |
| Liu S2018[19] | PubMed,Cochrane Library,Embase,CNKI,Wanfang Database,CBM. | inception to June 2016 | acute cerebralinfarction(ACI) | 1.CHIs①+AADN regimen VS AADN regimen2. CHI a+AADN regimen VS CHI b+AADN regimen | 1.the markedly effective rate2.improvement ofneurological impairment3.activities of daily living function4.death from all causes within the treatment and during the entire follow-up period | no |
| Xiang Y2017[20] | PubMed,Cochrane Library,Embase,CNKI,Wanfang Database,CBM,Chongqing VIP. | Inception to June 2016 | Stroke | 1.CMIs②+conventional treatment VS conventional treatment2. CMIs +conventional treatment VS placebo3.CMIs+ conventional treatment VS other CMIs4.CMIs+ conventional treatment VS western medicine | 1. the markedly effective rate2. neurological deficit score3. daily activity ability score4. adverse event incidence5.mortality6.cerebral hematoma changes7.safety evaluation of adverse/reactive events8.disability rate9.quality of life. | no |
| the current NMA | PubMed,Cochrane Library,Embase,CNKI,Wanfang Database,Sinomed ,Chongqing VIP. | inception to July 2018 | acute cerebralinfarction(ACI) | 1.CMI③ a + conventional treatment VS CMI b + conventional treatment2.CMI + conventional treatment VS conventional treatment. | 1. mortality 2. the rate of cerebrovascular event including recurrence event3.improvement of neurological impairment4.activities of daily living function5.adverse drug events6. the markedly effective rate | yes |

PS: 1.AADN inclide: aspirin + anticoagulants + dehydrant + neuroprotectant.

 2. CHIs① include: Ligustrazine injection ,Xueshuantong injection, Xuesaitong injection, Shuxuening injection, Dengzhanxixin injection, Dengzhanhuasu injection, Shuxuetong injection, Danhong injection, Fufangdanshen injection, Ginkgo Leaf Extract and Dipyridamole Injection, Mailuoning injection, Honghuahuangsesu injection, Shenxiong glucose injection, salviae miltiorrhizae ,ligustrazine hydrochloride injection, Danshen injection.

3. CMIs② include: Fufangdanshen injection, Danhong injection, Ginkgo Leaf Extract and Dipyridamole Injection, Dengzhanxixin injection, Dengzhanhuasu injection, Shuxuetong injection, salviae miltiorrhizae ,ligustrazine hydrochloride injection, Shuxuening injection, Mailuoning injection,Gegensu injection, Kudiezi injection, Danshen injection,Danshen polyphenolate injection, Xueshuantong injection, Xuesaitong injection,Xinding injection, Extract of Ginkgo Biloba Leaves Injection.

4. CMI③ include: Shuxuening injection, Xiangdan injection,Shuxuetong injection, Kudiezi injection,Xuesaitong injection, Xueshuantong injection, Dengzhanhuasu injection, Danhong injection, Dengzhanxixin injection,Danshen injection, Mailuoning injection,Xingnaojing injection

5. conventional treatment include: thrombolytic therapy, anticoagulant therapy, antiplatelet aggregation therapy and some other symptomatic supportive treatments, such as control of blood pressure and adjustment of blood lipids.